Characterising complex health needs and the use of preventive therapies in the older population: a population-based cohort analysis of UK primary care and hospital linked data
Open Access
- 31 January 2023
- journal article
- research article
- Published by Springer Nature in BMC Geriatrics
- Vol. 23 (1) , 1-9
Abstract
Background: While several definitions exist for multimorbidity, frailty or polypharmacy, it is yet unclear to what extent single healthcare markers capture the complexity of health-related needs in older people in the community. We aimed to identify and characterise older people with complex health needs based on healthcare resource use (unplanned hospitalisations or polypharmacy) or frailty using large population-based linked records. Methods: In this cohort study, data was extracted from UK primary care records (CPRD GOLD), with linked Hospital Episode Statistics inpatient data. People aged > 65 on 1st January 2010, registered in CPRD for ≥ 1 year were included. We identified complex health needs as the top quintile of unplanned hospitalisations, number of prescribed medicines, and electronic frailty index. We characterised all three cohorts, and quantified point-prevalence and incidence rates of preventive medicines use. Results: Overall, 90,597, 110,225 and 116,076 individuals were included in the hospitalisation, frailty, and polypharmacy cohorts respectively; 28,259 (5.9%) were in all three cohorts, while 277,332 (58.3%) were not in any (background population). Frailty and polypharmacy cohorts had the highest bi-directional overlap. Most comorbidities such as diabetes and chronic kidney disease were more common in the frailty and polypharmacy cohorts compared to the hospitalisation cohort. Generally, prevalence of preventive medicines use was highest in the polypharmacy cohort compared to the other two cohorts: For instance, one-year point-prevalence of statins was 64.2% in the polypharmacy cohort vs. 60.5% in the frailty cohort. Conclusions: Three distinct groups of older people with complex health needs were identified. Compared to the hospitalisation cohort, frailty and polypharmacy cohorts had more comorbidities and higher preventive therapies use. Research is needed into the benefit-risk of different definitions of complex health needs and use of preventive therapies in the older population.Keywords
Funding Information
- National Institute for Health and Care Research (SRF-2018-11-ST2-004)
This publication has 28 references indexed in Scilit:
- Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old peoplePharmacoepidemiology and Drug Safety, 2015
- The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995–2010BMC Medicine, 2015
- Using claims data to predict dependency in activities of daily living as a proxy for frailtyPharmacoepidemiology and Drug Safety, 2014
- A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomesJournal of Geriatric Oncology, 2013
- Comparing measures of multimorbidity to predict outcomes in primary care: a cross sectional studyFamily Practice, 2012
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional studyThe Lancet, 2012
- High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling MenClinical Pharmacology & Therapeutics, 2012
- Statin Prescribing in the Elderly in the NetherlandsDrugs & Aging, 2010
- Shift of statin use towards the elderly in 1995−2005: a nation‐wide register study in FinlandBritish Journal of Clinical Pharmacology, 2008
- Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United KingdomJournal of Human Hypertension, 2007